545results about "In-vivo testing preparations" patented technology

The present application provides a method for diagnosing and / or evaluating the presence or absence, severity or degree of the improvement of a retinal disease in a subject, which comprises determining and / or evaluating circulatory parameters, retinal function, retina morphology and / or visual relating quality of life (QOL).

A polymer dot includes a nitrogen-containing carbon dot that is free of benzene rings. A preparation method of the polymer dot includes: treating an A2 type monomer and a Bs type monomer by a one-pot synthesis to obtain the polymer dot. A use of the polymer dot is for manufacture of at least one of anti-inflammatory, antibacterial, and antioxidant compositions.

The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and / or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.

This invention discloses a strain of *Bifidobacterium pseudosporidis*, its preparation method, and its application in the prevention and treatment of METH addiction. *Bifidobacterium pseudosporidis* was isolated from fecal samples of individuals with low levels of METH addiction, and its strain identity was confirmed after isolation, purification, and identification. A METH addiction model was constructed by gavage colonization of C57 mice with this strain, and addiction-related indicators were detected in the model mice. The results showed that compared with the addiction model mice without colonization of this strain, the conditioned place preference score of the colonized group was significantly reduced (P<0.05). This *Bifidobacterium pseudosporidis* has a significant effect on improving METH addictive behavior and can be used to prepare biological agents with preventive and / or therapeutic functions for METH addiction. This invention reveals that *Bifidobacterium pseudosporidis* has the advantages of high safety and strong targeting, and can achieve the prevention and intervention of METH addiction without complex treatment equipment, providing a novel biological treatment option for the clinical treatment of METH addiction.

The present invention is directed to the use of ASC (Apoptosis Associated Speck-Like Protein Containing CARD) specks in the cancer immunotherapy. The present invention also relates to the compositions containing an ASC speck carrier formed by ASC proteins, and a tumor antigen for the treatment of cancer cells and tumors.

The application discloses a traceable tetrandrine hybrid nanocrystal and a preparation method and application thereof, and belongs to the technical field of biological medicine and nanomaterials. The hybrid nanocrystal is composed of tetrandrine and an AIE fluorescent probe. The AIE fluorescent probe is (E)-4-(4-(diphenylamino) styryl)-1-(3-(trimethylammonium) propyl) pyridine-1-bromide. The AIE fluorescent probe is embedded into the nanocrystal lattice of tetrandrine. The application further provides a preparation method of the hybrid nanocrystal. By embedding the environment-responsive AIE fluorescent probe into the TET nanocrystal lattice, the application realizes real-time and dynamic monitoring of the in-vivo and in-vitro dissolution and release process of the nanocrystal by using the characteristics of "aggregation state light emission and solution state quenching", and determines the anti-AD efficacy of the nanocrystal.

A method for detecting an immune-mediated inflammatory disease characterized by an increase in expression of MMP12, in a subject, a diagnostic drug containing a substance that specifically interacts with MMP12, and a therapeutic agent containing an MMP12 inhibitory substance.

Described herein are synthetic promoters and / or enhancers that are specific for cancer cells and methods of engineering synthetic cancer-specific promoters.

The subject matter of the present invention is a perfusion fluid in the form of an oil-in-water PFC nanoemulsion, methods of producing this perfusion fluid, and its use in particular for organ perfusion and as a blood substitute preparation.

The application discloses a preparation method of a tumor magnetic targeting guided magnetic heat self-enhancing nano diagnosis and treatment agent, and belongs to the technical field of cancer diagnosis and treatment. The preparation method comprises the following steps: S1, preparing NaGdF4:Nd / Yb Tm nanoparticles; and S2, preparing NaGdF4:Nd / Yb Tm@WFe2O4-NH2-PEG magnetic nanoparticles. The tumor magnetic targeting guided magnetic heat self-enhancing nano diagnosis and treatment agent provided by the application has good dispersity, strong magnetic attraction, can be efficiently enriched at a tumor site under magnetic guidance, can generate a large amount of heat in an alternating magnetic field to realize MHT treatment of the tumor, has near-infrared II region fluorescence imaging and MRI dual-mode imaging effects, thereby improving the diagnosis and treatment accuracy of the tumor and realizing diagnosis and treatment integration, has high biological safety and small toxic and side effects, and the preparation method is simple and easy to operate.

The present application belongs to the technical field of condensate, and particularly relates to a non-peptide small molecule condensate and preparation and application thereof. The present application provides a non-peptide small molecule condensate which is prepared by taking a small molecule shown in formula I as a precursor, wherein Y and Z are each independently NH, O or S, R = or X = O or S; R1 and R2 are each independently selected from H, C 3‑20 alkyl, -C 1‑8 alkylene-phenyl, -C 1‑8 alkylene-5-10-membered heteroaryl, -C 1‑8 alkylene-S-C 1‑8 alkyl, -C 1‑8 alkylene-SH, -C 1‑8 alkylene-O-C 1‑8 alkyl or -C 1‑8 alkylene-NH-C 1‑8 alkyl; and R1 and R2 are not H at the same time. The obtained condensate not only has good spontaneous non-classical fluorescence characteristics, but also has the abilities of drug loading and controllable release, and shows excellent resistance to enzymatic hydrolysis and good biocompatibility. Formula I

To provide an isolated nucleic acid molecule encoding a chimeric antigen receptor.SOLUTION: In one aspect, the chimeric antigen receptor is an isolated nucleic acid molecule comprising an anti-BCMA binding domain, a transmembrane domain and an intracellular signaling domain, the anti-BCMA binding domain comprising a heavy chain variable region comprising heavy chain complementarity determining region 1, heavy chain complementarity determining region 2 and heavy chain complementarity determining region 3, and a light chain variable region comprising light chain complementarity determining region 1, light chain complementarity determining region 2 and light chain complementarity determining region 3, and each of which comprising specific amino acid sequences.SELECTED DRAWING: None

This invention discloses a method for detecting the toxicity threshold of a substance based on a rat drinking experiment. The method of this invention includes the following steps: First, a drinking preference experiment is conducted, and then the toxicity threshold is determined: the amount of substance water and pure water consumed in the drinking preference is compared to determine the time when the rat begins to significantly avoid substance water, the mass of the toxic substance in the rat's body at that time is calculated, and the toxicity threshold of the rat is calculated; (3) dose conversion from rat to human: based on the interspecies dose conversion of body surface area, the toxicity threshold of the rat is first converted into the equivalent dose for humans to obtain the acute exposure dose, and then the acute exposure dose is converted into the chronic exposure dose for humans to obtain the substance toxicity threshold. This invention can accurately determine the toxicity threshold: it achieves toxicity assessment of low-dose exposure through spontaneous recognition behavior; it is easy to operate; and it is applicable to the toxicity assessment and non-destructive threshold determination of various substances such as environmental pollutants, chemical substances, and drugs.

The application discloses application of a divinyl tetrazine in cyclization of a linear polypeptide, and a structure formula of the divinyl tetrazine is; the linear polypeptide has at least two free mercapto groups, and the vinyl groups of the divinyl tetrazine are subjected to Michael addition reaction with corresponding mercapto groups to form a ring. The application provides a new use of the divinyl tetrazine, the divinyl tetrazine can be subjected to high-efficiency Michael addition reaction with two natural cysteine mercapto groups on the linear polypeptide through the vinyl groups, so that double-mercapto peg cyclization of the linear polypeptide is realized, and the purpose of limiting the conformation of the linear polypeptide and improving the stability of the linear polypeptide is achieved. Moreover, the divinyl tetrazine can be subjected to a reverse electron demand Diels-Alder reaction with trans-cyclooctene (TCO) after the two vinyl groups are subjected to reaction with mercapto groups, so that functional polypeptides can be modularly constructed by coupling with functional molecules modified with TCO, and related applications are realized.

Polymeric ocular inserts are provided that can be dissolvable when placed in the fornix of the eye. These inserts can comprise one or more polymers and a softening agent / plasticizer such that when inserted into the eye, the polymers and softening agent / plasticizer can absorb tears, dissolve, and slowly release a lubricant into the tear film to lubricate and protect the ocular surface for a prolonged duration. Increasing the residence time on the ocular surface to achieve more sustained relief can decrease the frequency of dosing and the patient burden typically associated with topical drop usage. These polymeric ocular inserts can also comprise one or more pharmaceutically active agents.

The application relates to a method for constructing a rat model of chronic obstructive pulmonary disease (COPD) related pulmonary arterial hypertension and application thereof, and belongs to the technical field of animal disease model construction. The method selects 6-8-week-old, 220+ / -10g healthy male SD rats, and all the rats are adaptively fed in a standard SPF level animal room for 7 days; then the rats are divided into a Con group and a COPD-PH group; the rats in the COPD-PH group are given 1mg / mL lipopolysaccharide by airway instillation on the first day and the 14th day; the rats are placed in a self-made whole-body inhalation smoking box for 1h every day from the 2nd day to the 13th day and from the 15th day to the 30th day; the rats enter a low-oxygen box for 8h every day during the light period from the 2nd day to the 13th day and from the 15th day to the 30th day; the rat model can simultaneously reproduce the characteristics of COPD and typical changes of pulmonary arterial hypertension, the right ventricular systolic pressure can be stably increased to 40-50mmHg, the right ventricular hypertrophy index can reach 0.40-0.50, the pulmonary vascular remodeling and inflammation are significant, and various indexes are stable and good in repeatability.

Methods for selectively expanding the number of T cells are disclosed. The methods can include modifying human T cells to express a TCR, where the TCR comprises a mouse constant region; producing a cell population comprising some human T cells that express the TCR and some human T cells that do not express the TCR; and culturing the cell population in the presence of (i) irradiated feeder cells, (ii) one or more cytokines, and (iii) an antibody or antigen-binding portion thereof, where the antibody has antigen specificity for the mouse constant region of the TCR, to selectively expand the number of T cells that express the TCR relative to the number of T cells that do not express the TCR. Related cell populations, pharmaceutical compositions, and methods for treating or preventing cancer are also disclosed. [Selection diagram] None

The present invention relates to obesity control by regulating the expression level of TREK1.

The present invention aims to provide a compound and its composition, kit, and application, primarily relating to the fields of medicinal chemistry, molecular probes, and biomedical engineering, particularly to EuK dimer compounds targeting PSMA, their pharmaceutical salts, and applications. The structure of the EuK dimer compound is shown in formula (I). This invention provides a novel cyanin-based EuK dimer compound targeting PSMA. This type of compound exhibits high affinity for prostate-specific membrane antigens, good in vivo pharmacokinetic properties, and is suitable for early diagnosis and staging of prostate cancer. It can also be used for intraoperative fluorescent navigation or clearance during prostatectomy. These high-affinity fluorescent probe molecules can specifically target tumors, accurately locate tumor boundaries, and provide real-time image navigation during surgery, thus improving surgical precision.

This invention belongs to the field of vertebrate technology, specifically relating to a method for constructing a complex inflammatory animal model in middle-aged and elderly individuals and its related applications. The method includes: selecting adult animals for adaptive feeding, daily subcutaneous injection of D-galactose to establish a susceptibility to aging and oxidative stress, and administering sodium dextran sulfate (DSS) solution within a specific time window to induce intestinal inflammation, forming a complex inflammatory state through gut-hepatic axis interactions. The constructed animal model simultaneously exhibits intestinal inflammatory damage, abnormal hepatic oxidative stress, and aging-related characteristics, realistically simulating the pathological process of gut-hepatic axis dysfunction in middle-aged and elderly individuals. This model is suitable for screening and evaluating drugs, medical nutrition products, and functional foods that improve gut-hepatic axis dysfunction, providing a reliable technical platform for research on related disease mechanisms and the development of interventional substances.

The present disclosure provides method of producing a non-human mammalian animal model containing human neural tissue, the method including: introducing a first human neural organoid into a central nervous system location of a newborn non-human mammal; introducing a second human neural organoid into the central nervous system location of the newborn non-human mammal to form an assembloid from the first human neural organoid and the second human neural organoid; and allowing the newborn non-human mammal to mature to produce the non-human mammalian animal model containing human neural tissue comprising GABAergic neurons; wherein the human neural tissue integrates into the circuit of the non-human animal and displays complex neural activity. Also provided are non-human mammalian animal models and methods of using the same.

The application relates to the technical field of animal model construction, in particular to a construction method and application of a spleen-kidney yang deficiency syndrome ovarian reserve function decline animal model. The construction method comprises the following steps: a model group animal is subjected to modeling by adopting the method of senna leaf water decoction gavage and hydrocortisone and cyclophosphamide injection, and a spleen-kidney yang deficiency syndrome ovarian reserve function decline animal model is obtained. In the application, the three of senna leaf, hydrocortisone and cyclophosphamide are used in synergy to administer the animal model, and the complex syndrome of the clinical spleen-kidney yang deficiency type DOR is accurately reproduced, and modern scientific basis is provided for the theories of traditional Chinese medicine such as the same treatment for different diseases.

The application discloses a novel AIE photosensitizer and a preparation method and application thereof. The AIE photosensitizer of the application comprises TDQ shown in the following structural formula, has superior photo-thermal conversion performance and photodynamic performance, and can be used for preparing a tumor diagnosis reagent or a tumor treatment drug. The co-loading liposome of TDQ and a senescence-inducing molecule (Ali) can be used as a multi-modal light diagnosis and treatment agent to realize efficient delivery of drugs to tumor tissues, and the photo-thermal therapy and the photodynamic therapy based on TDQ not only induce cell apoptosis through oxidative stress and mitochondrial dysfunction, but also trigger cancer cell senescence and promote the secretion of SASPs, so that the anti-tumor immunity is significantly enhanced, and finally the growth of primary tumors, tumor recurrence and re-metastasis are inhibited. The material of the application has simple preparation process, low cost, and is suitable for scale production and clinical medical use.

To provide trispecific and / or trivalent binding proteins.SOLUTION: Disclosed herein is a trispecific and / or trivalent binding protein comprising four polypeptide chains that form three antigen binding sites that specifically bind to one or more target proteins, where a first pair of the polypeptides that form the binding protein possesses double binding domains having crossover tropism, and a second pair of the polypeptides has a single variable domain that forms a single antigen binding site. In some embodiments, the binding protein comprises a binding site that binds to CD28 polypeptide, a binding site that binds to CD3 polypeptide, and a binding site that binds to a third polypeptide that binds to, for example, a tumor targeting protein.SELECTED DRAWING: Figure 1A

The present invention relates to methods and materials for embolization of one or more blood vessels (e.g., one or more arteries). For example, hydrogel compositions for embolization of one or more blood vessels (e.g., one or more arteries) within a mammal (e.g., a human) are provided.

The application discloses a microneedle, a microneedle patch and a preparation method and application thereof. The microneedle comprises drug-loaded microspheres and a matrix, the drug-loaded microspheres are distributed in the matrix, and the matrix comprises a matrix material and a thickening agent; wherein the matrix material comprises a beta-cyclodextrin derivative. The microneedle patch comprises the microneedle and a substrate, and the microneedle is distributed on the surface of the substrate. The microneedle has high mechanical strength and long-term stability, and the obtained microneedle patch can be applied to the fields of medicine and medical aesthetics.